Design of Topical Ocular Ciprofloxacin Nanoemulsion for the Management of Bacterial Keratitis

• المؤلفون الرئيسيون: Ahmed Adel Ali Youssef (مؤلف), Chuntian Cai (مؤلف), Narendar Dudhipala (مؤلف), Soumyajit Majumdar (مؤلف)
• التنسيق: كتاب
• منشور في: MDPI AG, 2021-03-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Bacterial keratitis (BK) is a critical ocular infection that can lead to serious visual disability. Ciprofloxacin (CIP), moxifloxacin (MOX), and levofloxacin (LFX) have been accepted as monotherapies by the US Food and Drug Administration for BK treatment. CIP is available commercially at 0.3% <i...